Skip to main content
Glama

Ensembl

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Despite annotations already declaring readOnly, idempotent, and non-destructive behavior, the description adds critical behavioral context: the USPTO PatentsView API sunset and soft-fail behavior, that empty sections mean real 'no data' not a bug, that FDA products showing none is expected for non-biologic companies, and that private companies return a notes line rather than a bare failure. These details go far beyond what annotations convey.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is appropriately sized for the tool's complexity — covering sources, return fields, edge cases, and input flexibility in about 250 words. It is front-loaded with the core purpose and examples. However, it is a single dense paragraph with heavy parenthetical asides; bulleted structure or section breaks would improve scannability without adding length.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

This tool has no output schema, so the description carries the full burden of explaining return values — and it does: cik, company_name, resolved_from/to, recent_filings with URIs, fundamentals, patents, federal_contracts, fda_products, hiring, news, LEI, sources_used, and sources_failed. It also details failure semantics (soft-fails, empty sections, private companies) and parameter options, so an agent has everything needed to call it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3, but the description adds meaningful semantics: the 'type' field accepts 'company' and 'ticker' interchangeably and behaves identically, 'value' can be a ticker, zero-padded CIK, or company name, and names resolve via SEC EDGAR's company-name match. It also clarifies future extension ('person/place coming soon') and gives concrete examples (AAPL, 0000320193, Moderna) that enrich the bare schema definitions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with a precise verb+resource statement: 'full cross-source profile of a US public company in ONE parallel call.' It distinguishes itself from sibling tools by explicitly saying 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view.' The example phrases ("Tell me about X", "brief me on Tesla") leave no doubt about what this tool does.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit when-to-use guidance: use when the user asks for a holistic view and prefer over chaining single-pack lookups. It also details accepted input forms (ticker, CIK, company name) and boundary cases like private companies returning resolved:false instead of failing. This effectively routes the agent to call this tool for broad entity profile requests rather than individual lookup tools.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Ensembl toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

There is heavy overlap in the ask_pipeworx family (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, bet_research, validate_claim) — several are near-identical 'route a natural-language question to a source' tools differing only by small qualifiers. ai_visibility_check vs scan_competitor_ai_presence and entity_profile vs compare_entities vs recent_changes also blur together. An agent could easily misselect among these.

Naming Consistency4/5

The dominant convention is snake_case verb_noun/noun_verb (list_subscriptions, scan_dependency, validate_claim, resolve_entity) which is fairly consistent, but there are several bare single-word verbs (lookup, sequence, variation, vep, xrefs, recall, remember, forget) that break the pattern. No camelCase is present, so the inconsistency is minor rather than chaotic.

Tool Count2/5

38 tools is heavy, and the overwhelming majority (~31) are Pipeworx meta-tools (subscriptions, memory, feedback, trend, discovery, llms.txt generation) that have nothing to do with the server's declared Ensembl identity. Only about 7 tools are actually genomics-related, so the count is inflated by off-domain additions that dilute the surface.

Completeness2/5

For the Ensembl domain, the surface covers gene lookup, symbol resolution, sequence retrieval, orthologs, SNPs, variant effect prediction, and xrefs — but misses major Ensembl capabilities like gene trees/families, regulatory features, comparative/multi-species alignments, expression data, phenotypes, GO/ontology annotations, and region/overlap queries. Conversely the Pipeworx tools are complete for their own domain but irrelevant here, leaving the declared domain notably incomplete.

Resources